A L-threonine transaldolase mutant and its application in the synthesis of L-p-methylsulfonylphenylserine

By mutation of the amino acid sequence of L-threonine transaldezyme and constructing recombinant microorganisms, the problems of many steps, low yield and high production costs in the preparation of L-p-methylsulfone phenylserine in the prior art are solved. It achieves efficient and economical catalytic effects and high purity products.

CN118497167BActive Publication Date: 2024-11-22ZHEJIANG HAOQING BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410943179.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-11-22
Estimated Expiration
2044-07-15

AI Technical Summary

Technical Problem

The prior art has problems such as many steps, low yield, poor stereoselectivity, high production cost, and difficult product separation and purification in the preparation of L-p-methylsulfone phenylserine, and the catalytic activity of wild-type threonine transaldezyme Low, it is difficult to meet industrial demand.

Method used

A L-threonine transaldegenerase mutant was designed to construct recombinant microorganisms for catalyzing glycine or threonine and p-methylsulfone benzaldehyde through mutations of amino acid sequence N22S, E104T and Y320R. The reaction produces L-p-methylsulfone phenylserine, and the catalyst form can be crude enzyme solution, engineered bacteria or immobilized enzyme.

Benefits of technology

It improves catalytic activity, improves conversion rate and three-dimensional purity of the product, simplifies the process, reduces solid waste and production costs, and achieves efficient and economical preparation of L-p-methylsulfone phenylserine.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides an L-threonine aldolase mutant and its application in the synthesis of L-p-methylsulfonylphenylserine, belonging to the field of enzyme engineering technology. The amino acid sequence of the L-threonine aldolase mutant is shown in SEQ ID NO.1, which relates to the field of enzyme engineering technology. The present invention also provides a coding gene of the L-threonine aldolase mutant, and the nucleotide sequence is shown in SEQ ID NO.2. The present invention also provides the application of the L-threonine aldolase mutant in the synthesis of L-p-methylsulfonylphenylserine. The L-threonine aldolase mutant can synthesize L-p-methylsulfonylphenylserine with p-methylsulfonylbenzaldehyde and threonine or glycine as substrates and 5-pyridoxal phosphate as a coenzyme. The L-threonine aldolase mutant of the present invention is used to prepare L-p-methylsulfonylphenylserine, and the ee value is>99%, and the de value range is 90-99%.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of enzyme engineering, relates to an L-threonine aldolase mutant, and specifically relates to an L-threonine aldolase mutant and application thereof in the synthesis of L-p-methylsulfonylphenylserine. Background Art

[0002] L-Methylsulfonylphenylserine, also known as (2S, 3R)-p-methylsulfonylphenylserine, is an important pharmaceutical intermediate, widely used in the preparation of human antibiotics, poultry and livestock antibiotics, and its representative drugs include chloramphenicol, thiamphenicol, florfenicol, etc. At present, it is mainly prepared by organic synthesis, which often has the disadvantages of many steps, low yield, poor stereoselectivity, etc.

[0003] There are also methods to synthesize 3-phenyl-L-serine derivatives by using benzaldehyde derivatives and glycine under the action of aldolase. However, this method still has the disadvantages of low conversion rate, poor stereoselectivity, and difficulty in separating and purifying the products, and is not suitable for industrialization. Therefore, a more gentle, efficient and economical method is explored to prepare such compounds.

[0004] Threonine aldolase can be used to catalyze the reaction of p-methylsulfonylbenzaldehyde and glycine or threonine to generate L-p-methylsulfonylphenylserine. This method has simple purification process operation, mild conditions, and greatly reduces solid waste and production costs. However, there is still a need for a threonine aldolase mutant with higher catalytic activity.

[0005] Patent CN110951799B provides an engineered strain of Escherichia coli BL21 (DE3) expressing threonine transaldolase (PsLTTA), which can achieve efficient biosynthesis of (2S, 3R)-p-methylsulfonylphenylserine, but the wild-type threonine transaldolase is used, which has low catalytic reaction activity and high production cost. Patent CN116790537A provides a threonine transaldolase mutant for the production of (2S, 3R)-p-methylsulfonylphenylserine, but the enzyme conversion yield is 93-95%, and the de value is 95%-96%, which still has room for further improvement. Summary of the invention

[0006] Terms and Claims of the Present Invention:

[0007] 1. As used herein, the articles "a", "an" and "the" include plural referents unless expressly limited to one or more referents otherwise.

[0008] 2. As used herein, numerical range: Unless otherwise expressly indicated, all ranges or ratios disclosed herein will be understood to include any and all sub-ranges or sub-ratios contained therein. For example, a range or ratio of 1 to 30 stated should be considered to be included between a minimum value of 1 and a maximum value of 30, and any sub-range or sub-ratio, integer, decimal, or sub-range or sub-ratio consisting of integers or decimals including the end points.

[0009] 3. As used herein, the term amino acid substitution or replacement refers to replacing an amino acid at a specific position in a polypeptide sequence with a different amino acid.

[0010] 4. As used herein, the term vector refers to a vector that can replicate autonomously in a host cell, preferably a multicopy vector. In addition, the vector usually has markers such as antibiotic resistance genes for selecting transformants. In addition, the vector may have a promoter and / or terminator for expressing the introduced gene. The vector may be, for example, a viral vector, a vector derived from a bacterial plasmid, a vector derived from a yeast plasmid, a vector derived from a phage, a cosmid, a phagemid, etc. A genetic engineering vector refers to a vector that enables the expression of a target gene in a cell, and is generally a linear or circular DNA molecule that includes a polynucleotide encoding a protein or polypeptide and is operably linked to an expression control sequence.

[0011] In order to solve the above problems, the present invention provides an L-threonine aldolase mutant and application thereof in the synthesis of L-methylsulfonylphenylserine.

[0012] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0013] In a first aspect, the present invention provides a L-threonine aldolase mutant, the amino acid sequence of which is shown in SEQ ID NO.1.

[0014] Specifically, the L-threonine aldolase mutant is obtained by mutating the wild-type L-threonine aldolase with accession number WP_232836050, and the specific mutations are N22S, E104T and Y320R.

[0015] In a second aspect, the present invention provides a nucleic acid encoding the above-mentioned L-threonine transaldolase mutant.

[0016] It is well known to those skilled in the art that, based on the principle of codon degeneracy and on the basis of knowing the amino acid sequence, those skilled in the art are capable of designing the specific nucleotide sequence of the nucleic acid expressing the L-threonine transaldolase mutant, and the design results have an infinite number of possibilities. Based on the design concept of the present invention, these nucleic acids should be within the scope of protection of the present invention.

[0017] Preferably, the present invention provides a specific nucleic acid, the nucleic acid sequence of which is shown in SEQ ID NO.2.

[0018] In a third aspect, the present invention provides an expression vector comprising the nucleic acid encoding the above-mentioned L-threonine transaldolase mutant.

[0019] Specifically, the expression vector is a pET30a plasmid into which the gene is inserted.

[0020] In a fourth aspect, the present invention provides a recombinant microorganism comprising the aforementioned genetic engineering vector.

[0021] In a fifth aspect, the present invention provides the use of the L-threonine aldolase mutant, the gene encoding the L-threonine aldolase mutant or the recombinant microorganism in the preparation of L-methylsulfonylphenylserine.

[0022] In a sixth aspect, the present invention also provides a method for preparing L-p-methylsulfonylphenylserine.

[0023] Specifically, the method for preparing L-p-methylsulfonylphenylserine uses glycine or threonine and p-methylsulfonylbenzaldehyde as substrates, pyridoxal phosphate as a coenzyme, and utilizes the L-threonine aldolase mutant or a cell expressing the L-threonine aldolase mutant as a catalyst to catalyze the production of L-p-methylsulfonylphenylserine.

[0024] More specifically, in the reaction system, the catalyst is used in the form of crude enzyme solution after cell disruption, or in the form of resting cells of engineered bacteria expressing recombinant enzymes, or in the form of purified pure enzymes or immobilized enzymes.

[0025] More specifically, the cell expressing the L-threonine transaldolase mutant may be the above-mentioned recombinant microorganism comprising the gene.

[0026] More specifically, the enzyme dosage is 50-500 mg / L, the substrate concentration is 10-100 g / L, the glycine or threonine concentration is 5-100 g / L, the pyridoxal 5-phosphate concentration is 0.01-0.1 g / L, the temperature is controlled at 25-45°C, the stirring speed is 70-300 rpm, and the pH of the phosphate buffer system is 7-8.

[0027] More specifically, the reaction can be carried out in an aqueous phase.

[0028] The beneficial effects of the present invention include:

[0029] The present invention provides an L-threonine aldolase mutant, a mutant encoding gene and a method for preparing L-p-methylsulfonylphenylserine. Compared with its original threonine aldolase, the mutant comprises amino acid substitutions at one or more positions. The method has high raw material utilization, and the product is easy to separate and purify, and has high conversion rate, yield and chiral purity; compared with the chemical catalytic process, the process is simple and less polluting. DETAILED DESCRIPTION

[0030] The present invention will be further described in detail below in conjunction with specific examples. The following examples are not intended to limit the present invention, but are only intended to illustrate the present invention. The experimental methods used in the following examples are generally conventional, unless otherwise specified, and the materials, reagents, etc. used in the following examples are commercially available, unless otherwise specified.

[0031] Example 1 Construction of engineered bacteria producing mutant threonine transaldolase

[0032] 1. Choose from Actinocorallia populi , the wild-type L-threonine aldolase with accession number WP_232836050, the amino acid sequence was converted into a nucleotide sequence according to the codon preference of Escherichia coli, the mutation site was designed, and the mutated nucleotide sequence was fully synthesized by chemical method (GenScript Biotechnology). The synthesized sequence is shown in SEQ ID NO.2, and the synthesized sequence was integrated into the expression vector pET-30a with the insertion sites of NdeI and BglII to construct a recombinant plasmid.

[0033] Table 1

[0034] SEQ ID NO. sequence 1 MetThrSerProSerGluProProValLeuHisAspAlaSerSerArgGlyPheAlaSerAspSerTyrAlaGlyIleHisProGluAlaLeuAlaAlaMetAlaAlaAlaAsnGlyGlyHisGlnThrSerTyrGlyAspAspValTyrThrAlaArgLeuGlnGluValPheGlnArgHisPheGlyProAlaAlaGlnAlaPheProValPheAsnGlyThrGlyAlaAsnValValGlyLeuSerAlaMetThrLysArgTrpSerAlaValIleAlaAlaGluThrAlaHisIleAsnValAspThrCysGlyAlaProGluLysValAlaGlyIleLysLeuLeuThrValProThrProAspGlyArgLeuThrProGluLeuValAspArgGlnAlaTrpGlyTrpGlyAspGluHisArgAlaGlnProHisValValSerLeuThrGlnSerThrGluLeuGlyThrValTyrAlaProGluGluIleArgAlaLeuAlaAspHisAlaHisGluArgGlyMetLeuValHisLeuAspGlySerArgLeuAlaAsnAlaAlaAlaAlaLeuGlyValProMetArgGluPheThrThrAspAlaGlyValAspValLeuSerPheGlyGlyThrLysAsnGlyLeuMetLeuGlyGluAlaValValValLeuAsnProGluLeuAlaProSerIleLysTyrLeuArgLysSerAlaMetGlnLeuAlaSerLysMetArgPheValSerAlaGlnLeuLeuAlaLeuLeuGluGlyAspLeuTrpLeuArgAsnAlaArgHisAlaAsnAlaMetAlaAlaArgLeuAlaAspGlyValArgGlyLeuProGlyLeuGluIleThrArgProValGlnAlaAsnAlaValPheAlaValLeuProLysAspAlaThrGluArgLeuGlnLysArgPheArgPheArgThrTrpAspGlnHisThrGlyGluValArgTrpMetThrAlaPheAspThrThrGluGluAspValAspValPheAlaAlaAlaValAlaAlaAspLeuThrGly 2 atgacatcacctagtgaaccacccgtactacacgacgcatctagccgtggctttgcgtccgacagctacgcaggcatccacccggaggcattggcggcgatggcagctgcgaacggtggtcatcagaccagctacggcgatgatgtctataccgcacgcctgcaagaggttttccagcgtcactttggtccggcagcccaagcgttcccggttttcaacggcaccggtgcgaacgtagttggtctgtcggcgatgaccaagcgctggtccgcggtgatcgccgctgaaaccgctcacattaatgttgacacgtgcggtgcaccggagaaggtggcgggcatcaaactgttgaccgttccgaccccagatggtcgtttaactccggagctggtcgaccgccaggcgtggggttggggcgacgaacatcgtgctcaaccgcatgtagtgtctctgacgcagagcaccgagttaggtacggtttacgcgcctgaggaaattcgtgcactggcggatcatgcgcacgaaagaggcatgctggtgcatctggatggcagcagactcgcgaatgcggcggctgctctgggtgttccgatgcgtgaatttaccaccgatgcgggtgtggacgtgctgagctttggcggtacgaagaacggtctgatgctgggcgaagcggtcgttgttttgaatccggagctggccccaagcattaagtatctgcgtaaaagcgcaatgcagctggcgtccaaaatgaggttcgtgtctgcccaattgctggcgttgttggaaggtgacctgtggctgcgtaacgctcgtcacgcaaatgccatggcggctcgcttggcggacggcgtgcgcggtcttccgggtctcgagatcacgcgtccggtccaggcgaacgcggtgttcgccgtgctgccgaaagatgccaccgagcgcctccaaaagcgttttcgtttccgcacctgggatcagcacaccggggaagttcgttggatgaccgcgtttgacaccactgaggaagatgtcgacgtgttcgccgctgcggttgcagcggacctgacaggctaa

[0035] 2. Transform the constructed plasmid into E.coli The L-threonine aldolase mutant enzyme engineering bacteria were constructed in BL21 (DE3) competent cells, the plates were spread, single colonies were picked, and the PCR method was used to identify the successfully constructed positive transformants.

[0036] 3. The plasmid extracted from the positive transformant is verified by sequencing, and then the correctness of the mutation site is verified by sequencing. After verification, it is stored in sterile glycerol with a final concentration of 20% and stored at -80℃ for future use.

[0037] Example 2 Cultivation of bacteria

[0038] Preparation of LB liquid culture medium: 10 g / L peptone, 5 g / L yeast extract powder, 10 g / L NaCl, dissolve in deionized water and make up to volume, sterilize at 121°C for 20 min.

[0039] After the mutant threonine transaldehyde enzyme engineered bacteria were activated by streaking on a plate, a single colony was inoculated into 3 mL LB liquid medium containing 50 μg / mL kanamycin and cultured at 37°C with shaking for 16 hours. A 5% inoculum was transferred to 50 mL LB liquid medium containing 50 μg / mL kanamycin and cultured at 37°C with shaking until the OD600 reached about 0.4-0.6, IPTG was added to a final concentration of 50 μg / mL, and induced at 30°C for 10 hours.

[0040] After the culture was completed, the culture solution was centrifuged at 10,000 rpm for 5 min, the supernatant was discarded, and the bacteria were collected and stored in a -80°C ultra-low temperature refrigerator for later use.

[0041] Example 3 Preparation of L-p-methylsulfonylphenylserine by L-threonine transaldolase mutant in aqueous solution

[0042] Reaction system: p-methylsulfonylbenzaldehyde 0.1mol / L, glycine 0.15mol / L, reduced coenzyme 0.002mol / L, pyridoxal phosphate 1μmol / L, wet bacterial concentration 1g / L, phosphate buffer pH 8.0, reaction temperature 30°C. After 15 minutes of reaction, the reaction solution was centrifuged and the supernatant was taken. The concentration of substrate p-methylsulfonylbenzaldehyde and product L-p-methylsulfonylphenylserine in the supernatant and the de value of L-p-methylsulfonylphenylserine were detected by HPLC. The results are shown in Table 2.

[0043] HPLC conditions were as follows:

[0044] Column: Aliglent TC-C18 column (250 mm*4.6 mm*5 μm);

[0045] Mobile phase: PBS (50 mM, pH 8.0): acetonitrile = 85:15 (0-2 min), 50:50 (7-8 min), 85:15 (9-13 min);

[0046] Flow rate: 1 mL / min;

[0047] Column temperature: 30°C;

[0048] Detection wavelength: 235nm;

[0049] Table 2

[0050]

[0051] Comparative Example 1

[0052] Referring to Example 1-3, the wet bacteria related to L-threonine transaldolase before mutation were used and the effect was verified. The results are shown in Table 3.

[0053] Table 3

[0054]

[0055] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A L-threonine transaldolase mutant, characterized in that: The amino acid sequence of the L-threonine transaldolase mutant is shown in SEQ ID NO.

1.

2. A nucleic acid, characterized in that The nucleic acid encodes the L-threonine transaldolase mutant according to claim 1.

3. The nucleic acid according to claim 2, characterized in that The nucleic acid sequence is shown as SEQ ID NO.

2.

4. A genetically engineered cell, characterized in that: The genetically engineered cell comprises the nucleic acid according to any one of claims 2-3.

5. Use of the L-threonine aldolase mutant according to claim 1 in the preparation of L-p-methylsulfonylphenylserine.

6. Use of the nucleic acid according to any one of claims 2 to 3 in the preparation of L-p-methylsulfonylphenylserine.

7. Use of the genetically engineered cell according to claim 4 in the preparation of L-p-methylsulfonylphenylserine.

8. A method for preparing L-p-methylsulfonylphenylserine, characterized in that: The method uses the L-threonine aldolase mutant of claim 1 and / or the genetically engineered cell of claim 4 as a catalyst to react and generate L-p-methylsulfonylphenylserine.

9. The method according to claim 8, characterized in that The dosage of the L-threonine aldolase mutant is 50-500 mg / L, the genetically engineered cells are wet bacteria, and the final concentration is 1 g / L. The method uses p-methylsulfonylbenzaldehyde and glycine or threonine as substrates and pyridoxal phosphate as a coenzyme to react and generate L-p-methylsulfonylphenylserine. The p-methylsulfonylbenzaldehyde concentration is 10-100 g / L, the glycine or threonine concentration is 5-100 g / L, and the 5-pyridoxal phosphate concentration is 0.01-0.1 g / L.

10. The method according to any one of claims 8 to 9, characterized in that: The reaction temperature is 25-45°C, the stirring speed is 70-300rpm, and the pH of the phosphate buffer system is 7-8.